FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography

J Clin Endocrinol Metab. 2023 Jul 14;108(8):1958-1967. doi: 10.1210/clinem/dgad073.

Abstract

Context: The contribution of [18F]F-fluorocholine (FCH)-positron emission tomography (PET)/computed tomography (CT) in normocalcemic primary hyperparathyroidism (nPHPT) remains unknown.

Objective: To evaluate the sensitivity and specificity of FCH-PET/CT in a cohort of osteoporotic patients with nPHPT and discordant or negative [99mTc]Tc-sestamibi scintigraphy and ultrasonography who all underwent parathyroidectomy (PTX).

Design: Longitudinal retrospective cohort study in patients referred for osteoporosis with mild biological primary hyperparathyroidism.

Setting: Tertiary referral center with expertise in bone metabolism and surgical management of hyperparathyroidism.

Patients: Among 109 patients with PHPT analyzed, 3 groups were individualized according to total serum calcium (tCa) and ionized calcium (iCa): 32 patients with hypercalcemia (HtCa group), 39 patients with normal tCa and elevated iCa (NtCa group), and 38 patients with both normal tCa and iCa (NiCa). All patients had biochemical follow-up confirming or not the success of PTX.

Main outcome measures: To evaluate the performance of FCH-PET/CT in terms of sensitivity and specificity, and to compare with first-line imaging procedures in the setting of nPHPT.

Results: The sensitivity of FCH-PET/CT was 67% in the hypercalcemic group, 48% in the NtCa group (P = .05 vs HtCa), and 33% in the NiCa group (P = .004 vs HtCa). Specificity ranged from 97% to 99%. FCH-PET/CT was positive in 64.3% of patients with negative conventional imaging, with biochemical resolution after PTX in 77.8% of patients. Triple negative imaging was observed in 20 patients, with PHPT resolution in 85% of these patients.

Conclusion: This study highlights the contribution of FCH-PET/CT in a well-phenotyped cohort of normocalcemic patients with discordant or negative findings in [99mTc]Tc-sestamibi scintigraphy and ultrasonography. However, negative imaging in nPHPT does not rule out the possibility of surgical cure by an experienced surgeon.

Keywords: FCH-PET/CT; hyperplasia; normocalcemic primary hyperparathyroidism; surgery.

MeSH terms

  • Calcium
  • Choline
  • Humans
  • Hyperparathyroidism, Primary* / diagnostic imaging
  • Hyperparathyroidism, Primary* / surgery
  • Organotechnetium Compounds
  • Parathyroid Glands / surgery
  • Positron Emission Tomography Computed Tomography* / methods
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • Technetium Tc 99m Sestamibi
  • Ultrasonography / methods

Substances

  • 2'-(2-hydroxyphenyl)-2'-thiazoline-4'-carboxylic acid
  • N-nitrosothiazolidine-4-carboxylic acid
  • fluorocholine
  • Calcium
  • Technetium Tc 99m Sestamibi
  • fluoromethylcholine
  • Choline
  • Radiopharmaceuticals
  • Organotechnetium Compounds